Linked to EAHP statements:
Section 1: Introductory Statement and Governance
Section 2: Selection, Procurement and Distribution

ACPE UAN: 0475-0000-17-011-L04-P. A knowledge based activity.

Abstract 

Due to economic constraints, the introduction of the use of new technologies in health care (e.g., new molecular entities, medical devices, organisational models) need a thorough and structured evaluation of their effectiveness, safety, economic and ethical impact. In many countries this structured approach is performed at central level, generally by the national or regional approval agencies. In this process, some countries have applied what is called "managed entry agreements", which require some form of reimbursement/ discount when the drug is not effective as expected.

In others, everything is left at the hospital level, a process known as "hospital based HTA".

In any case, some level of evaluation needs to be performed at the local level in order to reach a decision to include or not the new technology in clinical practice.

Hospital pharmacists are involved in the process, given their task in new technologies evaluation for the inclusion in the formulary or medical device positive list, and in the monitoring of the correct use and outcomes.

Learning Objectives

After the seminar, the participant should be able to:
• appraise the different HTA approaches and their advantages and disadvantages;
• apply an evaluation of a new technology at local level;
• describe the monitoring of the impact of the introduction of a new technology in clinical practice.

Keywords: hospital based HTA, innovation, budget constraints, hospital formulary

* No conflict of interest has been declared.